Washington University
St Louis, Missouri, 63110, United States
NCT Number: NCT01625663
Barth syndrome (BTHS) is an X-linked disorder caused by abnormal cardiolipin metabolism and is characterized by skeletal and cardiomyopathy and high mortality rates. Through clinical metabolism and imaging studies and pluripotent stem cell induction and molecular techniques on skin biopsy samples, this project will produce novel translational information regarding the pathogenesis of BTHS, reveal potential targets for interventions and provide unique data regarding nutrient metabolism and abnormal cardiolipin and mitochondrial function. This project has the potential to provide information that could significantly improve morbidity and mortality in children and young adults with BTHS and may have relevance to other non-BTHS related conditions such as aging and adult heart failure.
Looking for future studies?
Notify Me8 year–35 year
Male
Observational
St Louis, Missouri, 63110, United States
Barth syndrome (BTHS) is an X-linked disorder characterized by abnormal cardiolipin metabolism, mitochondrial dysfunction, muscle wasting and heart failure. BTHS is a particularly significant disease as it is often fatal in childhood and there are no approved therapies for BTHS other than the standard treatment of heart failure. Therefore novel areas of research and platforms in which to test new therapies are highly needed. Through state-of-the-art and innovative methodologies, this project will focus on the novel role of skeletal muscle and heart nutrient (glucose, fatty acid, and amino acid) metabolism in the pathogenesis of BTHS. Phenotypic information regarding skeletal muscle and heart nutrient metabolism in BTHS and how it may relate to energy production and function of these organs is lacking and is significant as this may advance our understanding of the underlying pathogenesis of BTHS. With this understanding, safe and efficacious therapies can be targeted for BTHS. The investigators' overall hypothesis is that impaired fatty acid metabolism in skeletal muscle and the heart produces a fuel deficit in these organs leading to impaired energy production, exercise intolerance and heart failure. Further, as a consequence of impaired fatty acid metabolism in skeletal muscle and the heart, protein breakdown (wasting) in skeletal muscle and the heart occurs to provide amino acids as compensation for this inadequate fatty acid energy supply, thereby worsening heart and skeletal muscle function in BTHS. The investigators' aims to address this hypothesis in 30 young adults and children with BTHS and 30 healthy, age, puberty stage and activity level matched controls ages 8-35 years are:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: baseline
Whole-body fatty acid oxidation rate will be measured by 13C-labeled fatty acid stable isotope tracer infusion and mass spectrometry
Time frame: baseline
whole-body amino acid oxidation rate will be measured by 13C leucine stable isotope tracer infusion and mass spectrometry
Time frame: baseline
cardiac energetics will be measured by 31P magnetic resonance spectroscopy of the heart
Time frame: baseline
skeletal muscle energetics will be measured by 31P magnetic resonance spectroscopy
Time frame: baseline
Myocardial fatty acid oxidation rate will be measured by radio-isotope tracer infusion and PET imaging
Time frame: baseline
Left ventricular systolic strain will be measured by tissue Doppler echocardiography
Duke University
Other
Heart and Skeletal Muscle Metabolism, Energetics and Function in Barth Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03098797
Abnormalities, Multiple, Barth Syndrome
Baltimore, Maryland, United States
View Trial DetailsNCT01629459
Abnormalities, Multiple, Barth Syndrome
St Louis, Missouri, United States
View Trial DetailsNCT01194141
Abnormalities, Multiple, Barth Syndrome
View Trial DetailsNCT07531251
Abnormalities, Multiple, Barth Syndrome
Needham, Massachusetts, United States
View Trial Details